Lessons Learned: For patients with advanced hepatocellular carcinoma after failure of first-line sorafenib monotherapy, second-line axitinib provides modest efficacy with tolerable toxicity. The discrepant tumor responses and survival outcomes in trials using axitinib as salvage therapy highlight the importance of optimal patient selection with the aid of clinical biomarkers.
Background: Multikinase inhibitors have been effective treatment for hepatocellular carcinoma (HCC). This multicenter phase II study explored the efficacy and safety of second-line axitinib for advanced HCC.
Methods: Patients with advanced HCC and Child-Pugh A liver function, experiencing progression on first-line sorafenib monotherapy, were eligible. Axitinib 5 mg twice daily was given continuously with allowed dose escalation. Tumor assessment was performed according to RECIST version 1.1. The primary endpoint was rate of disease control.
Results: From April 2011 to March 2016, 45 patients were enrolled. Thirty-seven patients (82%) tested positive for hepatitis B surface antigen. The disease control rate was 62.2%, and the response rate was 6.7%, according to RECIST criteria. Median progression-free survival (PFS) and overall survival (OS) were 2.2 months and 10.1 months, respectively. Treatment-related adverse events were compatible with previous reports of axitinib.
Conclusion: Second-line axitinib has moderate activity and acceptable toxicity for patients with advanced HCC after failing the first-line sorafenib monotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485356 | PMC |
| http://dx.doi.org/10.1634/theoncologist.2020-0143 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety Analysis of Axitinib Combined with Sintilimab as Second-Line Treatment for Advanced Renal Cell Carcinoma: A Retrospective Study.
Arch Esp Urol
December 2024
Department of Emergency Surgery, Qingdao Eighth People's Hospital, 266000 Qingdao, Shandong, China.
Background: Targeted therapies, including axitinib, a vascular endothelial growth factor receptor inhibitor, and sintilimab, a programmed cell death protein-1 inhibitor, have shown promise in the treatment of advanced renal cell carcinoma (RCC). Although their individual efficacies have been demonstrated, the potential synergistic effects of combining these two agents are still being explored.
Methods: This study retrospectively analysed patients with advanced RCC admitted to our hospital from January 2022 to December 2023.
Pattern of care and treatment outcomes of metastatic non-clear cell kidney cancer: a single centre experience from India.
Ecancermedicalscience
September 2024
Uro-Surgery, Tata Medical Center, 14 MAR (EW), New Town, Rajarhat, Kolkata 700160, West Bengal, India.
Background: Non-clear-cell renal cell carcinoma (nccRCC) refers to a rare diverse heterogeneous group of tumours; usually treated with immune check point inhibitors and or tyrosine kinase inhibitors (TKIs). Prospective large-scale data from Asian countries is limited.
Methods: This is a retrospective study of patients with metastatic nccRCC treated at Tata Medical Centre, Kolkata, India, from 2012 to 2022.
Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population.
Future Oncol
October 2024
Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK.
Renal cell carcinoma (RCC) is the seventh commonest cancer in the UK, where first-line (1L) sunitinib and second-line (2L) axitinib are treatment options. Retrospective, non-interventional data from the Christie NHS Foundation Trust (Manchester, UK). The primary end point was median progression-free survival (mPFS).
View Article and Find Full Text PDFArticle Synopsis
- - Axitinib, a drug used for advanced kidney cancer, is being tested for effectiveness against glioblastoma, a severe brain tumor, and shows improved results when combined with other treatments
- - Research indicates that axitinib can lead to cellular senescence (aging) in both tumor and normal cells, but using the antioxidant N-Acetyl-L-Cysteine (NAC) may limit this effect in normal cells while preserving its anti-cancer properties
- - The study reveals that NAC combined with axitinib enhances blood vessel health in brain tumors and protects against liver damage from axitinib, suggesting a potential for better treatment outcomes with reduced side effects
The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy.
World J Urol
September 2024
Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Japan.
Purpose: Metastatic non-clear cell renal cell carcinoma (nccRCC) is a heterogeneous disease with a poor prognosis and is treated with immunotherapy (IO)-based combinations according to the clear cell renal cell carcinoma. Tyrosine-kinase inhibitors (TKIs), such as cabozantinib and axitinib, are commonly used as the 2nd line therapy after 1st line IO combination therapy, but their efficacy as 2nd line TKI therapy for nccRCC is unknown. In this study, we performed a retrospective multicenter analysis of nccRCC patients who were previously treated with IO combination therapy and received 2nd line TKIs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!